International Clinical Trial: Phase III Single-Center, Randomized Controlled, Open-Label Clinical Study of Olanzapine 5mg Combined with Standard Triple Antiemetic Regimen in Breast Cancer Patients Receiving Highly Emetogenic Chemotherapy Regimens

Geneva, Feb. 13 -- International Clinical Trials Registry received information related to the study (ChiCTR2600118281) titled 'Phase III Single-Center, Randomized Controlled, Open-Label Clinical Study of Olanzapine 5mg Combined with Standard Triple Antiemetic Regimen in Breast Cancer Patients Receiving Highly Emetogenic Chemotherapy Regimens' on Feb. 4.

Study Type: Interventional study

Study Design: Parallel

Primary Sponsor: The First Affiliated Hospital of Zhengzhou University

Condition: Chemotherapy-induced nausea and vomiting in breast cancer

Intervention: Experimental group:Standard triple antiemetic regimen combined with 5mg olanzapine tablets

Recruitment Status: Recruiting

Phase: 3

Date of First Enrollment: 2026-02-04 ...